Itamar's WatchPAT gets nod from Blues
By HME News Staff
Updated Wed November 6, 2019
CAESAREA, Israel - Itamar Medical has received coverage for its WatchPAT as a home sleep apnea diagnostic test by Blue Shield of California (BSC) and the Blue Cross Blue Shield Federal Employee Plan (BCBS FEP). The inclusion of WatchPAT and PAT technology follows an assessment, Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome, recently released by Blue Cross Blue Shield Association Evidence Street. “The inclusion of WatchPAT as a recommended test for sleep apnea in the BCBS Evidence Street assessment is an important validation of the clinical value that Itamar's PAT technology provides,” said Gilad Glick, president and CEO. The company also noted the release of the Medicare 2020 Fee Schedule, which it says contains changes to home sleep apnea diagnostic coding that should support and expand the use of WatchPAT technology.
Comments